Bovine respiratory syncytial virus antigen protein

Abstract

The invention discloses a bovine respiratory syncytial virus antigen protein. Compared with SEQ AAL90052.1, at least two sites are substituted by cysteines in the amino acid sequence of the bovine respiratory syncytial virus antigen protein, and the substituted cysteines are connected by disulfide bonds; on such basis, intramolecular disulfide bond, hole filling, single strand connection and other improvements are carried out; and meanwhile, the invention also provides a preparation method of the antigen protein. By using the techniques and theories of protein crystallography, the structural changes of the protein in the virus infection and pathopoiesis process are determined; and the key virus protein is subjected to gene engineering modification according to the structural change result, thereby obtaining the protein antigen which is infective without pathopoiesis and can cause high-efficiency response of the animal body antibody. The bovine respiratory syncytial virus antigen protein can effectively prevent and treat bovine respiratory syncytial virus infection, can be developed into an ideal viral vaccine to effectively control and prevent the loss caused by virus infection, and thus, has important economic and social meanings.

Description

technical field [0001] The invention belongs to the technical field of biological product preparation, and relates to a bovine respiratory syncytial virus antigen protein and a preparation method thereof. Background technique [0002] Bovine Respiration Syncytial Virus (BRSV) infection can cause bovine respiratory diseases, and is listed as an important bovine disease in European Community countries after bovine mucosal disease (BVD) and bovine infectious rhinotracheitis (IBR). one of the diseases. The disease is prevalent worldwide, and its harmfulness is that the incidence of BRSV infection reaches as high as 60%-80%, and the mortality rate reaches more than 20% in some outbreaks, causing great economic losses to the cattle industry. Although this BRSV has been included in the research and development category since the 1970s, ideal drugs and vaccines have not been developed due to various reasons. Although there have been reports on various inactivated, attenuated, reco...

AI Technical Summary

Problems solved by technology

With the continuous advancement of human knowledge, the limitations of traditional vaccines are increasingly revealed: (1) animal and human viruses need to be cultured in animal cells, which makes the cost of vaccine production very high; (2) pathogenic viruses in vaccines The substance may not be completely killed or sufficiently attenuated during the vaccine production process, which will cause the vaccine to contain highly toxic pathogenic substances, which in turn will cause the disease to spread in a wider range; (3) Attenuated strains may occur mutation, disease-causing

Images